Trial Profile
A Randomised, Double-Blind, Placebo-Controlled, 3-Period Cross-Over Study to Evaluate the Effect of Two Doses of GSK2190915 on the Allergen-Induced Early Asthmatic Response in Subjects With Mild Asthma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Fiboflapon (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 08 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Aug 2009 Actual patient number (17) added as reported by ClinicalTrials.gov.
- 08 Aug 2009 Actual end date (1 Jul 2009) added as reported by ClinicalTrials.gov.